KANSL1 and ovarian carcinoma: A study on human ovarian cancer found that KANSL1 is amplified and/or rearranged in ovarian cancer, associated with the lymphocyte profile, a biomarker for response to histone deacetylase inhibition, and could potentially drive the expression of genes related to immune response (Fejzo et al., 2020).